Similar articles for PMID: 28009682

Year	Number of Results
2010	1
2011	5
2012	14
2013	10
2014	13
2015	14
2016	13
2017	9
2018	32
2019	13
2020	11
2021	12
2022	10
2023	5
2024	0

1

Outcomes With Fidaxomicin Therapy in Clostridium difficile Infection.

Spiceland CM, Khanna S, Pardi DS. Spiceland CM, et al. J Clin Gastroenterol. 2018 Feb;52(2):151-154. doi: 10.1097/MCG.0000000000000769. J Clin Gastroenterol. 2018. PMID: 28009682

2

Clinical outcomes of fidaxomicin vs oral vancomycin in recurrent Clostridium difficile infection.

Tieu JD, Williams RJ 2nd, Skrepnek GH, Gentry CA. Tieu JD, et al. J Clin Pharm Ther. 2019 Apr;44(2):220-228. doi: 10.1111/jcpt.12771. Epub 2018 Oct 22. J Clin Pharm Ther. 2019. PMID: 30350418

3

Effect of using fidaxomicin on recurrent Clostridium difficile infection.

Biggs M, Iqbal T, Holden E, Clewer V, Garvey MI. Biggs M, et al. J Hosp Infect. 2019 Jun;102(2):165-167. doi: 10.1016/j.jhin.2018.12.018. Epub 2019 Jan 4. J Hosp Infect. 2019. PMID: 30615960

4

Single centre clinical experience with fidaxomicin in the treatment of Clostridium difficile infection in Slovakia.

Novotný M, Jarčuška P, Gombošová L, Hockicko J, Hockicková I, Rovňáková A, Zahornacký O, Schréter I, Dorko E, Rimárová K. Novotný M, et al. Cent Eur J Public Health. 2018 Dec;26 Suppl:S76-S80. doi: 10.21101/cejph.a5476. Cent Eur J Public Health. 2018. PMID: 30817879 Free article.

5

Fidaxomicin for the treatment of Clostridium difficile infection (CDI) in at-risk patients with inflammatory bowel disease, fulminant CDI, renal impairment or hepatic impairment: a retrospective study of routine clinical use (ANEMONE).

Vehreschild MJGT, Taori S, Goldenberg SD, Thalhammer F, Bouza E, van Oene J, Wetherill G, Georgopali A. Vehreschild MJGT, et al. Eur J Clin Microbiol Infect Dis. 2018 Nov;37(11):2097-2106. doi: 10.1007/s10096-018-3344-1. Epub 2018 Aug 11. Eur J Clin Microbiol Infect Dis. 2018. PMID: 30099637 Free PMC article.

6

An antimicrobial stewardship program's real-world experience with fidaxomicin for treatment of Clostridium difficile infection: a case series.

Vargo CA, Bauer KA, Mangino JE, Johnston JE, Goff DA. Vargo CA, et al. Pharmacotherapy. 2014 Sep;34(9):901-9. doi: 10.1002/phar.1451. Epub 2014 Jun 5. Pharmacotherapy. 2014. PMID: 24898525

7

Fidaxomicin--the new drug for Clostridium difficile infection.

Vaishnavi C. Vaishnavi C. Indian J Med Res. 2015 Apr;141(4):398-407. doi: 10.4103/0971-5916.159251. Indian J Med Res. 2015. PMID: 26112840 Free PMC article. Review.

8

Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection: EXTEND study subgroup analyses.

Cornely OA, Vehreschild MJGT, Adomakoh N, Georgopali A, Karas A, Kazeem G, Guery B. Cornely OA, et al. Eur J Clin Microbiol Infect Dis. 2019 Jun;38(6):1187-1194. doi: 10.1007/s10096-019-03525-y. Epub 2019 Mar 25. Eur J Clin Microbiol Infect Dis. 2019. PMID: 30911926 Free PMC article. Clinical Trial.

9

Effectiveness of fidaxomicin versus oral vancomycin in the treatment of recurrent clostridioides difficile.

Rinaldi A, Reed EE, Stevenson KB, Coe K, Smith JM. Rinaldi A, et al. J Clin Pharm Ther. 2021 Aug;46(4):993-998. doi: 10.1111/jcpt.13387. Epub 2021 Feb 20. J Clin Pharm Ther. 2021. PMID: 33609052

10

Current and emerging management options for Clostridium difficile infection: what is the role of fidaxomicin?

Cornely OA. Cornely OA. Clin Microbiol Infect. 2012 Dec;18 Suppl 6:28-35. doi: 10.1111/1469-0691.12012. Clin Microbiol Infect. 2012. PMID: 23121552 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

141 results

Results by year